Ivica Lazúrová

Ivica Lazúrová

Auto-generated profile, based on publicly available information

Ivica Lazúrová

P.J. Safarik University

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
ILIvica Lazúrová
Ivica Lazúrová
IJIvana Jochmanová
Ivana Jochmanová
KBKarim Benhatchi
Karim Benhatchi
ŠSŠtefan Sotak
Štefan Sotak

19 April 2011 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
KBKarim Benhatchi
Karim Benhatchi
IJIvana Jochmanová
Ivana Jochmanová
VHViera Habalová
Viera Habalová
HWHedviga Wagnerová
Hedviga Wagnerová
ILIvica Lazúrová
Ivica Lazúrová

23 March 2015 in Lupus
Verified
Journal Article
Closed access
IJI Jochmanová
I Jochmanová
ZLZ Lazúrová
Z Lazúrová
MRM Rudnay
M Rudnay
IBI Bačová
I Bačová
MMMária Mareková
Mária Mareková
ILI Lazúrová
I Lazúrová
Over the past few years, there has been evidence of the increasing prevalence of autoimmune diseases. Autoimmune diseases consist of many complex disorders of unknown etiology resulting in immune responses to self-antigens. The immune system, and its function, is under complex and integrated control and its disruption can be triggered by multiple factors. Autoimmunity development is influenced by multiple factors and is thought to be a result of interactions between genetic and environmental factors. Here, we review the role of a specific environmental factor, bisphenol A (BPA), in the pathogenesis of autoimmune diseases. BPA belongs to the group of environmental estrogens that have been identified as risk factors involved in the development of autoimmune diseases.

2 November 2012 in Polish Archives of Internal Medicine
Verified
Journal Article
Closed access
ILIvica Lazúrová
Ivica Lazúrová
KBKarim Benhatchi
Karim Benhatchi
DOI: 10.20452/pamw.1499, Published online: November 02, 2012, Authors: Ivica Lazúrová, Karim Benhatchi

18 February 2024 in Thyroid®
Verified
Journal Article
Closed access
RARoberto Attanasio
Roberto Attanasio
MŽMiloš Žarković
Miloš Žarković
EPEnrico Papini
Enrico Papini
ENEndre V. Nagy
Endre V. Nagy
RNRoberto Negro
Roberto Negro
LHLaszlo Hegedus
Laszlo Hegedus
Background. Hypothyroidism is common, however, aspects of its treatment remain controversial. Our survey aimed at documenting treatment choices of European thyroid specialists and exploring how patients’ persistent symptoms, clinician demographics, and geo-economic factors relate to treatment choices. Methods. 17,247 thyroid specialists from 28 countries were invited to participate in an online questionnaire survey. The survey included respondent demographic data and treatment choices for hypothyroid patients with persistent symptoms. Geo-economic data for each country were included in the analyses. Results. The response rate was 32.9% (6,058 respondents out of 17,247 invitees). Levothyroxine (LT4) was the initial treatment preferred by the majority (98.3%). Persistent symptoms despite normal serum thyrotropin (TSH) while receiving LT4 treatment were reported to affect up to 10.0% of patients by 75.4% of respondents, while 28.4% reported an increasing such trend in the past five years. The principal explanations offered for patients’ persistent symptoms were psychosocial factors (77.1%), comorbidities (69.2%), and unrealistic patient expectations (61.0%). Combination treatment with LT4 + liothyronine (LT3) was chosen by 40.0% of respondents for patients who complained of persistent symptoms despite a normal TSH. This option was selected more frequently by female thyroid specialists, with high-volume practice, working in countries with high gross national income per capita. Conclusions. The perception of patients’ dissatisfaction reported by physicians seems lower than that described by hypothyroid patients in previous surveys. LT4+LT3 treatment is used frequently by thyroid specialists in Europe for persistent hypothyroid-like symptoms even if they generally attribute such symptoms to non-endocrine causes and despite the evidence of non-superiority of the combined over the LT4 therapy. Pressure by dissatisfied patients on their physicians for LT3-containing treatments is a likely explanation. The association of the therapeutic choices with the clinician demographic characteristics and geo-economic factors in Europe is a novel information and requires further investigation.

12 April 2013 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
LTL’ubomír Tomáš
L’ubomír Tomáš
ILIvica Lazúrová
Ivica Lazúrová
MOMária Oetterová
Mária Oetterová
LPLýdia Pundová
Lýdia Pundová
DPDarina Petrášová
Darina Petrášová
MSMartin Studenčan
Martin Studenčan